Happe, Svenja

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hogl, Birgit"],["dc.contributor.author","Gschliesser, V."],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiu, G."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, Al W."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Kohnen, Ralf"],["dc.date.accessioned","2018-11-07T08:48:03Z"],["dc.date.available","2018-11-07T08:48:03Z"],["dc.date.issued","2005"],["dc.format.extent","A272"],["dc.identifier.isi","000228906101316"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21113"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","19th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Denver, CO"],["dc.relation.issn","0161-8105"],["dc.title","Augmentation during long-term treatment with L-DOPA in restless legs syndrome: Results of a multicentric study in Europe"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","696"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","703"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Grote, Ludger"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Mathis, Johannes"],["dc.contributor.author","Saletu-Zyhlarz, Gerda M."],["dc.contributor.author","Kohnen, Ralf"],["dc.date.accessioned","2018-11-07T11:03:11Z"],["dc.date.available","2018-11-07T11:03:11Z"],["dc.date.issued","2007"],["dc.description.abstract","We report the first large-scale double-blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Methods: Patients with idiopathic RLS were treated with fixed daily doses of 2 or 3 mg CAB or 200 or 300 mg levodopa for 30 weeks. Efficacy was assessed by changes in the IRLS (International RLS Severity Scale) and by time to disconfirmation of treatment due to loss of efficacy or augmentation. 361 of 418 screened patients (age 58 +/- 12 years, 71% females) were randomly assigned and treated (CAB: n = 178; levodopa: n = 183) in 51 centers of four European countries. Baseline IRLS total score was 25.7 +/- 6.8. The baseline-adjusted mean change from baseline to week 6 in IRLS sum score was d = -16.1 in the CAB group and d = -9.5 in the levodopa group (d = -6.6, P < 0.0001). More patients in the levodopa group (24.0%) than in the CAB group (11.9%, P = 0.0029, log-rank test) discontinued because of loss of efficacy (14.2% vs. 7.9%, P = 0.0290) or augmentation (9.8% vs. 4.0%, P = 0.0412). Adverse events (AEs) occurred in 83.1% of the CAB group and in 77.6% of the levodopa group. In both groups, most frequent AEs were gastrointestinal symptoms (CAB: 55.6%, levodopa: 30.6%, P < 0.0001). This first large-scale active controlled study in RLS showed superior efficacy of cabergoline versus levodopa after a 30-week long-term therapy. Tolerability was found more favorable with levodopa than with cabergoline. (c) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21401"],["dc.identifier.isi","000246213100015"],["dc.identifier.pmid","17274039"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51559"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0885-3185"],["dc.title","Cabergoline compared to levodopa in the treatment of patients with severe Restless Legs Syndrome: Results from a multi-center, randomized, active controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","230"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","237"],["dc.bibliographiccitation.volume","257"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Gschliesser, Viola"],["dc.contributor.author","Egatz, Renata"],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Hening, Wayne A."],["dc.contributor.author","Allen, Richard P."],["dc.date.accessioned","2018-11-07T08:46:22Z"],["dc.date.available","2018-11-07T08:46:22Z"],["dc.date.issued","2010"],["dc.description.abstract","The European Restless Legs Syndrome (RLS) Study Group performed the first multi-center, long-term study systematically evaluating RLS augmentation under levodopa treatment. This prospective, open-label 6-month study was conducted in six European countries and included 65 patients (85% treatment naive) with idiopathic RLS. Levodopa was flexibly up-titrated to a maximum dose of 600 mg/day. Presence of augmentation was diagnosed independently by two international experts using established criteria. In addition to the augmentation severity rating scale (ASRS), changes in RLS severity (International RLS severity rating scale (IRLS), clinical global impression (CGI)) were analyzed. Sixty patients provided evaluable data, 35 completed the trial and 25 dropped out. Augmentation occurred in 60% (36/60) of patients, causing 11.7% (7/60) to drop out. Median time to occurrence of augmentation was 71 days. The mean maximum dose of levodopa was 311 mg/day (SD: 105). Patients with augmentation compared to those without were significantly more likely to be on higher doses of levodopa (a parts per thousand yen300 mg, 83 vs. 54%, P = 0.03) and to show less improvement of symptom severity (IRLS, P = 0.039). Augmentation was common with levodopa, but could be tolerated by most patients during this 6-month trial. Patients should be followed over longer periods to determine if dropout rates increase with time."],["dc.description.sponsorship","Pharmacia (now Pfizer) USA"],["dc.identifier.doi","10.1007/s00415-009-5299-8"],["dc.identifier.isi","000274251700011"],["dc.identifier.pmid","19756826"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6747"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20677"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0340-5354"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S495"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","S504"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Klein, Christine"],["dc.contributor.author","Nass, Alexander"],["dc.contributor.author","Montagna, Pasquale"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","O'Keeffe, Shaun"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Provini, Federica"],["dc.contributor.author","Pramstaller, Peter P."],["dc.contributor.author","Sieminski, Mariusz"],["dc.contributor.author","Sonka, Karel"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Wetter, Thomas C."],["dc.contributor.author","Winkelmann, Juliane"],["dc.contributor.author","Zucconi, Marco"],["dc.date.accessioned","2018-11-07T11:07:07Z"],["dc.date.available","2018-11-07T11:07:07Z"],["dc.date.issued","2007"],["dc.description.abstract","The European Restless Leas Syndrome (RLS) Study Group (EURLSSG) is an association of European RLS experts who are actively involved in RLS research. A major aim of the Study Group is the development and continuous improvement of standards for diagnosis and treatment of RLS. Several members developed study designs and evaluation methods in investigator-initiated trials early in the 1990s, and all members have since contributed to many pivotal and nonpivotal drug trials for the treatment of RLS. The recommendations on clinical investigations of pharmacological treatment of RLS patients summarize the group's expertise and knowledge acquired through clinical trials. The recommendations primarily address how to plan and conduct confirmatory, randomized clinical studies in patients with idiopathic RLS. Advice is presented for the diagnosis of RLS and clinical and polysomnographic inclusion and exclusion criteria. Primary and secondary endpoints for an evaluation of efficacy are based on a critical description of validated methods for both short- and long-term trials, also in special populations (children, pregnant women, elderly patients). The recommendations include the assessment of augmentation. Finally, general issues including the evaluation of safety and tolerability, as well as specific neurological and cardiovascular risks and sleep attacks/daytime somnolence, are discussed. The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols. (C) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21538"],["dc.identifier.isi","000251605200015"],["dc.identifier.pmid","17530666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52479"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Scientific Symposium and Augmentation Workshop on Restless Leg Syndrome"],["dc.relation.eventlocation","Max Planck Inst Phys Complex Syst, Munich, GERMANY"],["dc.relation.issn","1531-8257"],["dc.relation.issn","0885-3185"],["dc.title","Clinical trials in restless legs syndrome - Recommendations of the European RLS study group (EURLSSG)"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Schwank, S."],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Caldir, S."],["dc.date.accessioned","2018-11-07T08:48:10Z"],["dc.date.available","2018-11-07T08:48:10Z"],["dc.date.issued","2005"],["dc.format.extent","A277"],["dc.identifier.isi","000228906101331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21146"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Academy Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","19th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Denver, CO"],["dc.relation.issn","0161-8105"],["dc.title","Results from the first active controlled trial to investigate efficacy of cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","455"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Sleep Medicine"],["dc.bibliographiccitation.lastpage","463"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","de Weerd, Al W."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Gschliesser, Viola"],["dc.contributor.author","Egatz, Renata"],["dc.contributor.author","Cabrero, Belen"],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Hening, Wayne A."],["dc.contributor.author","Allen, Richard P."],["dc.date.accessioned","2018-11-07T11:00:28Z"],["dc.date.available","2018-11-07T11:00:28Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: Augmentation is the main complication during long-term dopaminergic treatment of restless legs syndrome (RLS) and reflects an overall increase in RLS severity. Its severity varies considerably from a minor problem to a devastating exacerbation of disease. Despite its clinical relevance, systematic evaluations have rarely been undertaken and there has been no development of methods to assess the severity of augmentation. To fill this gap, the European RLS Study Group (EURLSSG) has developed the Augmentation Severity Rating Scale (ASRS), using three items that assess the degree of change in three specific dimensions of augmentation. The changes in each dimension are summed to give an ASRS total score. Methods: The ASRS was developed to cover the basic dimensions defining RLS augmentation. The items were developed by an interactive process involving professional and patient input. The ASRS that was evaluated included four major items and two alternative forms of one item. The validation was conducted using 63 (85%) mostly untreated RLS patients from six centers, who were treated for six months with levodopa (L-Dopa) (up to 500 mg/day, as clinically needed). Two consecutive assessments before and at baseline measured test-retest reliability. Consecutive ASRS ratings by two independent raters on a subsample of patients evaluated inter-rater reliability. Comparison with clinical severity ratings of two independent experts provided external validation of the ASRS. Comparison of patients with and without augmentation with regard to the items and the total score of the ASRS added discriminant validity. Results: Sixty patients (63% females, mean age: 53 years, baseline International RLS Severity Rating (IRLS) score 24.7 +/- 5.2) were treated with a median daily dose of 300 mg L-Dopa (range: 50-500 mg). Thirty-six patients (60%) experienced augmentation. Item analyses indicated that one item could be removed as it did not contribute significantly to the test score and only one form of the duplicated item needed to be used. The final ASRS then included three items. Test-retest reliability for the total score was rho = 0.72, and inter-rater reliability was rcc = 0.94. Cronbach's alpha was 0.62. Validity as assessed by the correlation between the worst ASRS total score during the trial and the expert rating was p = 0.72. ASRS total score differed between patients without versus with augmentation (mean: 7.4 (standard deviation (SD) = 4.0) vs. 2.0 (2.7) (P < 0.0001). Conclusions: The ASRS is a reliable and valid scale to measure the severity of augmentation. Due to the need to systematically quantify augmentation for both long-term efficacy and tolerability, the ASRS may become a useful tool to monitor augmentation in future clinical trials. (C) 2007 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.sleep.2007.03.023"],["dc.identifier.isi","000248955800001"],["dc.identifier.pmid","17543579"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50923"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1878-5506"],["dc.relation.issn","1389-9457"],["dc.title","Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Gschliessl, V."],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiu, G."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","de Weerd, Al W."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Kohnen, Ralf"],["dc.date.accessioned","2018-11-07T10:42:30Z"],["dc.date.available","2018-11-07T10:42:30Z"],["dc.date.issued","2006"],["dc.format.extent","A289"],["dc.identifier.isi","000237916701226"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46812"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Acad Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","20th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Salt Lake City, UT"],["dc.relation.issn","0161-8105"],["dc.title","Augmentation during long-term treatment with L-DOPA: Results of a multicentre study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","A288"],["dc.bibliographiccitation.journal","SLEEP"],["dc.bibliographiccitation.lastpage","A289"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","de Weerd, Al W."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Allen, R."],["dc.contributor.author","Kohnen, Ralf"],["dc.date.accessioned","2018-11-07T10:42:27Z"],["dc.date.available","2018-11-07T10:42:27Z"],["dc.date.issued","2006"],["dc.identifier.isi","000237916701224"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46801"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Acad Sleep Medicine"],["dc.publisher.place","Westchester"],["dc.relation.conference","20th Annual Meeting of the Associated-Professional-Sleep-Societies"],["dc.relation.eventlocation","Salt Lake City, UT"],["dc.relation.issn","0161-8105"],["dc.title","Validation of the augmentation severity rating scale (ASRS): Results from a study of the European Restless Legs Syndrome Group (EU-RLSG)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1040"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","1046"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Oertel, Wolfgang Hermann"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Bodenschatz, R."],["dc.contributor.author","Peglau, Ines"],["dc.contributor.author","Warmuth, R."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Geisler, Peter"],["dc.contributor.author","Cassel, Werner"],["dc.contributor.author","Leroux, M."],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.date.accessioned","2018-11-07T09:14:39Z"],["dc.date.available","2018-11-07T09:14:39Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: To assess the efficacy and safety of the dopamine agonist cabergoline in the treatment of patients with idiopathic restless legs syndrome (CATOR study). Methods: Patients with moderate to severe restless legs syndrome (RLS) were randomly assigned to cabergoline (single evening dose: 2 mg) or placebo and treated for 5 weeks in a double-blind, multicenter polysomnography (PSG) trial. The primary efficacy measures were the periodic leg movements during sleep arousal index (PLMS-AI) and sleep efficiency. These and further PSG variables were monitored by centrally evaluated PSG. Severity of RLS was assessed using the International RLS Study Group Severity Scale (IRLS), the RLS-6 scales, the Sleep Questionnaire Form A (SF-A; quality of sleep), and the Quality of Life for RLS questionnaire. Results: Forty-three patients were treated and 40 patients were evaluated with PSG ( age 56 +/- 10 years, 73% women). Cabergoline was superior to placebo in terms of the PLMS-AI (-17.7 +/- 16.4 vs -4.5 +/- 20.0 placebo; p = 0.0024), sleep efficiency (+6.2 +/- 13.9% vs +3.3 +/- 11.7%; p = 0.0443), PLMS index (p = 0.0014), PLM index (p = 0.0012), and total sleep time (p = 0.0443). Improvements in IRLS total score (-23.7 +/- 11.2 vs -7.9 +/- 11.0 placebo; p = 0.0002), RLS-6 severity scales during the night (p = 0.0010) and during the day (p = 0.0018), Clinical Global Impressions severity item (p = 0.0003), sleep quality (p = 0.0180), SF-A sleep quality (p = 0.0371), and QoL-RLS (p = 0.0247) were larger in patients treated with cabergoline compared with the placebo group. Adverse events were only mild and well-known side effects of dopamine agonists. Conclusion: Single-evening cabergoline is an efficacious and well-tolerated short-term therapy for sensorimotor symptoms of restless legs syndrome and associated sleep disturbances."],["dc.identifier.doi","10.1212/01.wnl.0000237742.08297.22"],["dc.identifier.isi","000240749900023"],["dc.identifier.pmid","16931508"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27469"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0028-3878"],["dc.title","Efficacy of cabergoline in restless legs syndrome - A placebo-controlled study with polysomnography (CATOR)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S476"],["dc.bibliographiccitation.journal","Movement Disorders"],["dc.bibliographiccitation.lastpage","S484"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Earley, Christopher J."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Rye, David"],["dc.contributor.author","Winkelmann, Juliane"],["dc.date.accessioned","2018-11-07T11:07:06Z"],["dc.date.available","2018-11-07T11:07:06Z"],["dc.date.issued","2007"],["dc.description.abstract","Augmentation constitutes the main complication of long-term dopaminergic treatment in restless legs syndrome (RLS). Although this condition was first described in 1996, and is characterized by an overall increase in severity of RLS symptoms (including earlier onset of symptoms during the day, faster onset of symptoms when at rest, expansion to the upper limbs and trunk, and shorter duration of the treatment effect), precise diagnostic criteria were not established until 2003. These criteria have recently been updated to form a new definition of augmentation based on multicentric studies. The present article reviews our current knowledge on clinical diagnosis, evaluation, pathophysiology, and treatment recommendations for this condition. (C) 2007 Movement Disorder Society."],["dc.identifier.doi","10.1002/mds.21610"],["dc.identifier.isi","000251605200013"],["dc.identifier.pmid","17580331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52476"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Malden"],["dc.relation.conference","Scientific Symposium and Augmentation Workshop on Restless Leg Syndrome"],["dc.relation.eventlocation","Max Planck Inst Phys Complex Syst, Munich, GERMANY"],["dc.relation.issn","0885-3185"],["dc.title","Augmentation as a treatment complication of restless legs syndrome: Concept and management"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]